Excision BioTherapeutics reported new preclinical results for its hepatitis B virus (HBV) gene-editing candidate EBT-107, showing reductions in intrahepatic HBV DNA and suppression of de novo HBV DNA integration in HBV-infected primary human hepatocytes and in two chronic HBV mouse models. Deep-sequencing analyses found no increase in overall integration and no differences in chromosomal translocations compared with controls. The company said these data support advancing EBT-107 toward first-in-human studies, noting that current antivirals reduce viral load but do not eliminate cccDNA, the reservoir that enables persistent infection.1
In the press release, CEO Daniel Dornbusch said in vitro and in vivo studies indicate the dual guide RNA editing strategy can eliminate intrahepatic HBV DNA molecules while suppressing integration that may contribute to hepatocarcinogenesis, and that safety signals remain favorable, with fragmentation of episomal HBV DNA not increasing host-genome integration or chromosomal rearrangements in treated liver samples.¹ Clinical efficacy has not yet been established.1